Perrigo (PRGO) to Restructure BCH Omega Pharma Belgium Business; Will Terminate EuroGenerics Agreement

Perrigo Company plc (NYSE: PRGO) announced its intention to restructure the Branded Consumer Healthcare's ("BCH") Omega Pharma Belgium business (which includes Omega Pharma Belgium NV, Etixx NV and Biover NV), located in Nazareth, Venecoweg 26 (Belgium) to improve the financial profile and enhance focus of the business on branded consumer OTC products.

Perrigo's CEO John Hendrickson stated, "Consistent with our previously announced comprehensive portfolio review, we are today announcing specific actions to streamline operations and safeguard the future of our BCH Belgium business. The action plan for Belgium is directed at enhancing long-term profitability by focusing our efforts on growing our OTC brand portfolio. Today's announcement furthers the Perrigo Board of Directors' and management's commitment to delivering shareholder value."

To improve the financial profile of the BCH Belgium business, the Company:

• Signed a definitive agreement with EuroGenerics NV to terminate their existing distribution agreement to distribute product for STADA Arzneimittel AG in Belgium effective December 31, 2016
• Signed a definitive agreement to sell the Etixx brand and its business effective January 1, 2017
• Allowed for the natural expiration of a distribution agreement with MEDA AB effective December 2016, and
• Initiated the consultation process in Belgium to better align the organization to current business and market dynamics

These combined businesses and products are forecasted to achieve calendar year 2016 net sales of approximately $155 million dollars with no contribution to margin.

The employees of Omega Pharma Belgium NV, Etixx NV and Biover NV have been informed in detail of the business analysis and the intention to restructure the business operations. Today's announcement marks the beginning of a consultation period with employees, as required by Belgian legislation, regarding the intention to restructure the Omega Pharma Belgian operational business unit. This restructuring plan is only related to Omega Pharma Belgium NV, Etixx NV and Biover NV and only activities related to Omega Pharma Belgium are involved in this plan.

You May Also Be Interested In

• Fisker (FSR) files form 10-K, sees more job cuts, reiterates going concern doubts
• CEL-SCI Corp (CVM) Appoints Mario Gobbo to Its Board
• Renault posts revenue beat in Q1, confirms full-year outlook